Stocks Mixed as S&P 500 Hits New Highsby Terry Bingman 29.03.2024Chemours stock was a major loser on the market, while Apple stock performed poorly. Home Depot stock is extended, and ...
Democrats Raise Concerns Over CBP One Appby Lilu Anderson 29.03.2024A group of 36 lawmakers penned a letter urging the US administration to address the barriers and glitches in the ...
Top Ways to Invest Tax Refund in 2024by Mark Eisenberg 28.03.2024Many featured companies on Money advertise with them, but they are not clients of any investment adviser on the page. ...
Home Depot $18.3 Billion Deal Targets Pro Builder Marketby Mark Eisenberg 28.03.2024Home Depot stock eased 0.3% on Thursday, despite a strong performance earlier in the week. Builders FirstSource also saw a ...
Bitcoin Surges as Traditional Investors Buy from Old Whalesby John Darbie 28.03.2024Bitcoin's price surged from $966 to $19,666 in 2017, with ownership changes lasting for 332 days. New whale entities have ...
Oil Prices Rise as Investors Rethink US Inventory Databy Mark Eisenberg 28.03.2024U.S. WTI crude futures for May delivery rise 0.5% to $81.79 a barrel. Both benchmarks on track for third month ...
Investing in Britain’s Critical Gas Infrastructure: Future-Proofing Energyby Terry Bingman 28.03.2024National Gas is partnering with government stakeholders, regulators, and industrial partners to future-proof the energy system. Results from their initiative ...
LG’s $74 Billion Investment in South Korea: AI, Biotech, Batteries, Clean Tech, Displaysby Lilu Anderson 28.03.2024LG plans to invest $74.3 billion in South Korea through 2028, focusing on AI, biotechnology, batteries, clean tech, and displays. ...
David Gardner: The Challenges of Angel Investing | WRAL TechWireby Mark Eisenberg 28.03.2024Angel investing can be difficult yet rewarding. Angels learn a lot and enjoy their involvement. Despite challenges, it is an ...
NextCure, Inc.: Promising Growth Potential or Risky Investment?by Mark Eisenberg 28.03.2024NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.